Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000199038 | SCV000252023 | pathogenic | not provided | 2012-09-14 | criteria provided, single submitter | clinical testing | The c.540 G>C mutation in the OPA3 gene changes the Stop codon at amino acid position 180 to a Tyrosine codon and results in the extension of the OPA3 protein by 97 amino acids, denoted p.Stop180Tyrext97. This extension of 97 amino acids is predicted to affect the function of the OPA3 protein. Although this mutation has not been previously reported to our knowledge, it is expected to be a disease-associated mutation. The variant is found in MITONUC-MITOP panel(s). |
Labcorp Genetics |
RCV001853188 | SCV002190039 | uncertain significance | 3-Methylglutaconic aciduria type 3; Optic atrophy 3 | 2021-12-11 | criteria provided, single submitter | clinical testing | This sequence change disrupts the translational stop signal of the OPA3 mRNA. It is expected to extend the length of the OPA3 protein by 97 additional amino acid residues. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with OPA3-related conditions. ClinVar contains an entry for this variant (Variation ID: 214928). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV000199038 | SCV005408865 | uncertain significance | not provided | 2023-10-31 | criteria provided, single submitter | clinical testing | PM2_moderate, PM4 |